AEROSOL DELIVERY OF THERAPEUTIC DRUGS TO PATIENTS WITH TUBERCULOSIS

向结核病患者气雾输送治疗药物

• 批准号: 6305883
• 负责人: Neil W. Schluger
• 金额: $ 2.1万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305883
• 关键词: HIV infections; Mycobacterium tuberculosis; alveolar macrophages; clinical research; clinical trial phase I; human subject; human therapy evaluation; immunotherapy; inhalation drug administration; interferon gamma; leukocyte activation /transformation; respiratory disorder chemotherapy; tuberculosis

This phase I/II trial will assess the safety of rh-IFN-gamma in the treatment of HIV-negative and HIV-positive patients with pulmonary tuberculosis, assess alveolar macrophage activation in patients with pulmonary tuberculosis before and after administration of IFN-gamma, and gather preliminary data on efficacy. The lab was used for blood separation, BAL analysis, ELISA, use of laminar flow hoods, PCR, DNA sequencing (manual), recombinant DNA techniques, RNA isolation, Western analysis, and oligonucleotide synthesis.

这项I/II期试验将评估rh-IFN-gamma治疗HIV阴性和HIV阳性肺结核患者的安全性，评估肺结核患者在使用IFN-gamma之前和之后肺泡巨噬细胞的活化情况，并收集有关功效的初步数据。 该实验室用于血液分离、BAL 分析、ELISA、层流罩的使用、PCR、DNA 测序（手动）、重组 DNA 技术、RNA 分离、Western 分析和寡核苷酸合成。